uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Consensus on biomarkers for neuroendocrine tumour disease
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences.
Yale Univ, Sch Med, New Haven, CT 06510 USA..
Erasmus MC, Endocrinol Sect, Dept Internal Med, Rotterdam, Netherlands..
Charite, D-13353 Berlin, Germany..
Show others and affiliations
2015 (English)In: The Lancet Oncology, ISSN 1470-2045, E-ISSN 1474-5488, Vol. 16, no 9, E435-E446 p.Article, review/survey (Refereed) PublishedText
Abstract [en]

Management of neuroendocrine neoplasia represents a clinical challenge because of its late presentation, lack of treatment options, and limitations in present imaging modalities and biomarkers to guide management. Monoanalyte biomarkers have poor sensitivity, specificity, and predictive ability. A National Cancer Institute summit, held in 2007, on neuroendocrine tumours noted biomarker limitations to be a crucial unmet need in the management of neuroendocrine tumours. A multinational consensus meeting of multidisciplinary experts in neuroendocrine tumours assessed the use of current biomarkers and defined the perquisites for novel biomarkers via the Delphi method. Consensus (at > 75%) was achieved for 88 (82%) of 107 assessment questions. The panel concluded that circulating multianalyte biomarkers provide the highest sensitivity and specifi city necessary for minimum disease detection and that this type of biomarker had sufficient information to predict treatment effectiveness and prognosis. The panel also concluded that no monoanalyte biomarker of neuroendocrine tumours has yet fulfilled these criteria and there is insufficient information to support the clinical use of miRNA or circulating tumour cells as useful prognostic markers for this disease. The panel considered that trials measuring multianalytes (eg, neuroendocrine gene transcripts) should also identify how such information can optimise the management of patients with neuroendocrine tumours.

Place, publisher, year, edition, pages
2015. Vol. 16, no 9, E435-E446 p.
National Category
Cancer and Oncology
URN: urn:nbn:se:uu:diva-274778ISI: 000363966100025PubMedID: 26370353OAI: oai:DiVA.org:uu-274778DiVA: diva2:897644
Available from: 2016-01-26 Created: 2016-01-26 Last updated: 2016-01-26Bibliographically approved

Open Access in DiVA

No full text


Search in DiVA

By author/editor
Öberg, Kjell
By organisation
Department of Medical Sciences
In the same journal
The Lancet Oncology
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 31 hits
ReferencesLink to record
Permanent link

Direct link